Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
复制标题
DOI：
10.1016/j.jisp.2017.10.003
复制
发表时间：
2018-01-01
期刊：
影响因子：
--
通讯作者：
King, Brett Andrew
中科院分区：
文献类型：
--
作者：
Liu, Lucy Yichu;King, Brett Andrew
斑秃（AA）是一种影响所有年龄段人群的自身免疫性疾病。目前没有治愈AA的方法，并且对于严重AA的高效疗法一直难以捉摸。最近，科学进步已经确定Janus激酶途径作为治疗靶点。美国食品和药物管理局批准的两种Janus激酶抑制剂托法替尼和鲁索替尼在开放标签临床试验中均显示出希望。本综述总结了托法替尼长期用于重度AA的结果。
Alopecia areata (AA) is an autoimmune disease affecting people of all ages. There is currently no cure for AA, and a highly efficacious therapy for severe AA has been elusive. Recently, scientific advances have identified the Janus kinase pathway as a target for treatment. Both Janus kinase inhibitors approved by the US Food and Drug Administration, tofacitinib and ruxolitinib, have shown promise in open-label clinical trials. This review summarizes the results of long-term use of tofacitinib in severe AA.